Beone Medicines Ltd Quick Ratio (ONC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Beone Medicines Ltd   (NASDAQ: ONC)

Beone Medicines Ltd 's Quick Ratio

ONC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 2.5 below Beone Medicines Ltd average.

Within Major Pharmaceutical Preparations industry 257 other companies have achieved higher Quick Ratio than Beone Medicines Ltd in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 926 to 1110.

Explain Quick Ratio?
How much Cash & cash equivalents ONC´s has?
What are ONC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -4.1 % -8.68 % -17.43 % 16.94 % 13.98 %
Y / Y Cash & cash equivalent Change 91.95 % 90.42 % 73.08 % 49.41 % 6.3 %
Quick Ratio MRQ 2.5 2.65 2.49 1.7 1.25
ONC's Total Ranking # 1110 # 926 # 546 # 1117 # 1355
Seq. Current Liabilities Change 16.98 % -0.95 % -22.78 % 7.18 % 11.4 %
Seq. Cash & cash equivalent Change 10.41 % 5.37 % 12.65 % 46.47 % 9.52 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 258
Healthcare Sector # 442
Overall Market # 1110


Quick Ratio Statistics
High Average Low
18.12 5.54 1.19
(Mar 31 2016)   (Dec 31 2024)




Financial Statements
Beone Medicines Ltd 's Current Liabilities $ 2,119 Millions Visit ONC's Balance sheet
Beone Medicines Ltd 's Cash & cash equivalent $ 5,290 Millions Visit ONC's Balance sheet
Source of ONC's Sales Visit ONC's Sales by Geography


Cumulative Beone Medicines Ltd 's Quick Ratio

ONC's Quick Ratio for the trailling 12 Months

ONC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -3.63 % 0.68 % 4.1 % 14.77 % 22.14 %
Y / Y Cash & cash equivalent TTM Growth 76.07 % 54.55 % 29.32 % 5.9 % -8.98 %
Quick Ratio TTM 2.3 1.96 1.65 1.36 1.26
Total Ranking TTM # 3881 # 3867 # 2455 # 3176 # 3176
Seq. Current Liabilities TTM Growth -1.1 % -2.05 % -4.4 % 4.07 % 3.32 %
Seq. Cash & cash equivalent TTM Growth 15.71 % 16.42 % 16.09 % 12.59 % 1.57 %

Quick ratio ranking by company, industry and sector >> Back to ONC Financial Strength Comparisons >> Go to Compare ONC Quick Ratio to its Competitors

On the trailing twelve months basis ONC Cash & cash equivalent soared by 91.95 % in Q2 2026 year on year, while Current Liabilities increased to $2,119 millions, this led to increase in in Beone Medicines Ltd 's Quick Ratio to 2.3, Quick Ratio remained below ONC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Beone Medicines Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3867 to 3881.

Explain Quick Ratio?
How much Cash & cash equivalents ONC´s has?
What are ONC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 886
Within the Market # 3881


trailing twelve months Quick Ratio Statistics
High Average Low
10.78 4.68 1.26
(Dec 31 2016)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions

Date modified: 2026-09-11T09:58:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.